Glaukos (GKOS) Stock Forecast & Price Target

Glaukos Corp has demonstrated strong growth in its Corneal Health segment, with a compound annual growth rate (CAGR) of approximately 15.2% worldwide since 2020, highlighting robust performance in both U.S. markets (15.7% CAGR) and international markets (11.7% CAGR). Additionally, the anticipated adoption of Epioxa shows promising trends, with expected average utilization increasing to 28.7%, 31.1%, and 33.9% in the years 2026, 2027, and 2028, respectively, indicating potential for significant market penetration. These factors collectively contribute to a favorable outlook for Glaukos's financial performance and stock potential.

Glaukos Corp faces a concerning outlook due to multiple factors impacting its growth trajectory, including the limited growth rates in its Corneal Health segment, which show annual growth rates of only about 8.9% globally and 2.3% outside the U.S. This sluggish performance is compounded by potential headwinds such as slower market adoption of its iDose TR implant and the iStent infinite, along with increasing competition in the minimally invasive glaucoma surgery (MIGS) market. Moreover, uncertainties surrounding changes in the reimbursement landscape and delays in product launches add further risk to the company’s financial forecasts, suggesting a challenging future for Glaukos's stock performance.